Eloralintide
Shop EloralintideEloralintide is a special medicine made to help people lose weight.
Benefits
What Eloralintide Helps With
The benefits people report — backed by research.
Weight management (2)
Free: The Peptide Stack Cheat-Sheet
You just read the research on Eloralintide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
Self-reported & vendor-suggested
Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.
SubQ
- Subcutaneous injection (Dose 1, 2, 3, or 4) 60/100Rated 60/100Source typeSpecialist communityIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Mild to moderate side effectsMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
- Mild side effectsMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ withpower.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Eloralintide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
News
Latest on Eloralintide
Dated, sourced reporting that mentions Eloralintide.
Novel amylin receptor agonist induces ‘clinically meaningful’ weight loss
Eli Lilly's investigational amylin receptor agonist, eloralintide, demonstrated 'clinically meaningful' weight loss in a phase 2 trial. The highest dose achieved up to 20.1% weight reduction at 48 weeks. The drug showed an acceptable tolerability profile, particularly when using dose escalation to mitigate gastrointestinal side effects.
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Eli Lilly announced positive Phase 2 results for eloralintide, a selective amylin receptor agonist, showing placebo-adjusted weight loss ranging from 9.1% to 19.7% over 48 weeks. The drug demonstrated a favorable tolerability profile and improvements in cardiometabolic markers. Based on these data, Lilly plans to initiate Phase 3 trials for obesity treatment next month.
Wondering how Eloralintide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →